Brought to you by 
Aslan partners with Array in its first development pact; deal expanded
30 Jan 2023
Executive Summary
Aslan Pharmaceuticals Pte. Ltd. (oncology, inflammation, and respiratory disease therapies) has licensed worldwide rights to Array BioPharma Inc.’s (cancer and inflammation) ARRY543, which is entering Phase II for solid tumors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aslan partners with Array in its first development pact; deal expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice